Smith & Nephew plc ADR Stock
Smith & Nephew plc ADR Stock
Smith & Nephew plc ADR gained 2.880% today.
Pros and Cons of Smith & Nephew plc ADR in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Smith & Nephew plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Smith & Nephew plc ADR | 2.880% | -2.721% | 4.380% | 19.167% | 2.143% | 9.160% | -20.556% |
| Smith & Nephew plc | 1.290% | -3.258% | 2.628% | 15.989% | 0.281% | 8.817% | -21.676% |
| Dexcom Inc. | 1.420% | 3.540% | 6.143% | -27.180% | 4.606% | -40.563% | -18.227% |
| Thermo Fisher Scientific Inc. | -0.850% | 0.301% | 9.941% | -2.146% | 7.972% | -0.983% | 28.023% |
Comments
Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew SNATS (NYSE:SNN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew plc (NYSE: SNN) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating on the stock.
Show more
Ratings data for SNN provided by MarketBeat
